Key result
Antithrombotic, antiplatelet, and fibrinolytic therapies significantly reduce morbidity and mortality in acute coronary syndrome.
Why the study?
The role of various pharmaceutical agents in different phases of acute coronary syndrome is complex and continuously evolving, necessitating a comprehensive review of antithrombotic therapy.
A review of the evolving role of antithrombotic, antiplatelet, and fibrinolytic therapies in the management of acute coronary syndrome.
Answers are grounded in this paper and cite their sources.
Supports broad ACS application; leaves open optimization of specific regimens amid evolving options.
Coronary heart disease is the leading cause of death in the US and the industrialized world. Ever since DeWood in 1980 demonstrated that a thrombus was the primary event leading to acute myocardial infarction and that they may subsequently lyse, the mainstay of therapy for the past 25 years has been antithrombotic therapy aimed at coronary thrombosis. There have been numerous advances in the treatment of acute coronary syndrome with antiplatelet, antithrombotic, and fibrinolytic agents that have significantly reduced morbidity and mortality. The role of various pharmaceutical agents in the different phases of acute coronary syndrome is a complex and ever changing field.7.
No takes yet. Share an insight, caveat, or question.
W L Duvall (2006) conducted a review in Acute coronary syndrome. Antithrombotic therapy was evaluated. Antithrombotic, antiplatelet, and fibrinolytic therapies have significantly reduced morbidity and mortality in acute coronary syndrome, though their specific roles remain complex and evolving.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: